{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,11]],"date-time":"2026-09-11T03:39:20Z","timestamp":1789097960844,"version":"build-2803163510"},"reference-count":42,"publisher":"Elsevier BV","issue":"6","license":[{"start":{"date-parts":[[2007,6,1]],"date-time":"2007-06-01T00:00:00Z","timestamp":1180656000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2007,6,1]],"date-time":"2007-06-01T00:00:00Z","timestamp":1180656000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"}],"content-domain":{"domain":["dmd.aspetjournals.org","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Drug Metabolism and Disposition"],"published-print":{"date-parts":[[2007,6]]},"DOI":"10.1124\/dmd.106.014472","type":"journal-article","created":{"date-parts":[[2007,3,2]],"date-time":"2007-03-02T04:04:26Z","timestamp":1172808266000},"page":"841-847","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":13,"title":["Evaluation of 3-O-Methylfluorescein as a Selective Fluorometric Substrate for CYP2C19 in Human Liver Microsomes"],"prefix":"10.1016","volume":"35","author":[{"given":"Sirimas","family":"Sudsakorn","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jeffrey","family":"Skell","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"David A.","family":"Williams","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Thomas J.","family":"O\u2019Shea","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hanlan","family":"Liu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1124\/dmd.106.014472_bib1","doi-asserted-by":"crossref","first-page":"715","DOI":"10.1124\/dmd.32.7.715","article-title":"An evaluation of the in vitro metabolism data for predicting the clearance and drug-drug interaction potential of CYP2C9 substrates","volume":"32","author":"Andersson","year":"2004","journal-title":"Drug Metab Dispos"},{"key":"10.1124\/dmd.106.014472_bib2","doi-asserted-by":"crossref","first-page":"1637","DOI":"10.1124\/dmd.105.005579","article-title":"Automated assessment of time-dependent inhibition of human cytochrome P450 enzymes using liquid chromatography-tandem mass spectrometry analysis","volume":"33","author":"Atkinson","year":"2005","journal-title":"Drug Metab Dispos"},{"key":"10.1124\/dmd.106.014472_bib3","first-page":"30","article-title":"Application of higher throughput screening (HTS) inhibition assays to evaluate the interaction of antiparasitic drugs with cytochrome P450S","volume":"29","author":"Bapiro","year":"2001","journal-title":"Drug Metab Dispos"},{"key":"10.1124\/dmd.106.014472_bib4","first-page":"1196","article-title":"The use of 3-[2-(N,N-diethyl-N-methylammonium)ethyl]-7-methoxy-4-methylcoumarin (AMMC) as a specific CYP2D6 probe in human liver microsomes","volume":"29","author":"Chauret","year":"2001","journal-title":"Drug Metab Dispos"},{"key":"10.1124\/dmd.106.014472_bib5","doi-asserted-by":"crossref","first-page":"215","DOI":"10.1006\/abio.1999.4348","article-title":"Description of a 96-well plate assay to measure cytochrome P4503A inhibition in human liver microsomes using a selective fluorescent probe","volume":"276","author":"Chauret","year":"1999","journal-title":"Anal Biochem"},{"key":"10.1124\/dmd.106.014472_bib6","doi-asserted-by":"crossref","first-page":"1005","DOI":"10.1124\/dmd.31.8.1005","article-title":"In vitro drug interaction of cytochrome P450: an evaluation of fluorogenic to conventional substrates","volume":"31","author":"Cohen","year":"2003","journal-title":"Drug Metab Dispos"},{"key":"10.1124\/dmd.106.014472_bib7","doi-asserted-by":"crossref","first-page":"188","DOI":"10.1006\/abio.1997.2145","article-title":"Microtiter plate assays for inhibition of human drug metabolizing cytochromes P450","volume":"248","author":"Crespi","year":"1997","journal-title":"Anal Biochem"},{"key":"10.1124\/dmd.106.014472_bib8","first-page":"23","article-title":"A method for the simultaneous evaluation of the activities of seven major human drug-metabolizing cytochrome P450s using an in vitro cocktail of probe substrates and fast gradient liquid chromatography tandem mass spectrometry","volume":"29","author":"Dierks","year":"2001","journal-title":"Drug Metab Dispos"},{"key":"10.1124\/dmd.106.014472_bib9","doi-asserted-by":"crossref","first-page":"572","DOI":"10.1016\/S0009-9236(97)90054-0","article-title":"Ticlopidine inhibition of phenytoin metabolism mediated by potent inhibition of CYP2C19","volume":"62","author":"Donahue","year":"1997","journal-title":"Clin Pharmacol Ther"},{"key":"10.1124\/dmd.106.014472_bib10","doi-asserted-by":"crossref","first-page":"699","DOI":"10.1124\/dmd.32.7.699","article-title":"Fluorescence-based assays for screening nine cytochrome P450 (P450) activities in intact cells expressing individual human P450 enzymes","volume":"32","author":"Donato","year":"2004","journal-title":"Drug Metab Dispos"},{"key":"10.1124\/dmd.106.014472_bib11","doi-asserted-by":"crossref","first-page":"375","DOI":"10.1002\/bdd.374","article-title":"Rapid determination of enzyme activities of recombinant human cytochromes P450, human liver microsomes and hepatocytes","volume":"24","author":"Ghosal","year":"2003","journal-title":"Biopharm Drug Dispos"},{"key":"10.1124\/dmd.106.014472_bib12","doi-asserted-by":"crossref","first-page":"214","DOI":"10.2165\/00003088-199733030-00004","article-title":"Pharmacokinetic interaction with felbamate","volume":"33","author":"Glue","year":"1997","journal-title":"Clin Pharmacokinet"},{"key":"10.1124\/dmd.106.014472_bib13","doi-asserted-by":"crossref","first-page":"12112","DOI":"10.1021\/bi010254c","article-title":"Ticlopidine as a selective mechanism-based inhibitor of human cytochrome P450 2C19","volume":"40","author":"Ha-Duong","year":"2001","journal-title":"Biochemistry"},{"key":"10.1124\/dmd.106.014472_bib14","doi-asserted-by":"crossref","first-page":"387","DOI":"10.1016\/S0031-6997(24)01372-3","article-title":"Prediction of pharmacokinetic alterations caused by drug-drug interaction: metabolic interaction in the liver","volume":"50","author":"Ito","year":"1998","journal-title":"Pharmacol Rev"},{"key":"10.1124\/dmd.106.014472_bib15","doi-asserted-by":"crossref","first-page":"849","DOI":"10.1016\/S0090-9556(25)08427-2","article-title":"In vitro inhibition by macrolide antibiotics and azole antifungals","volume":"22","author":"Jurima-Romet","year":"1994","journal-title":"Drug Metab Dispos"},{"key":"10.1124\/dmd.106.014472_bib16","first-page":"775","article-title":"Evaluation of omeprazole and lansoprazole as inhibitors of cytochrome P450 isoforms","volume":"26","author":"Ko","year":"1998","journal-title":"Drug Metab Dispos"},{"key":"10.1124\/dmd.106.014472_bib17","doi-asserted-by":"crossref","first-page":"343","DOI":"10.1046\/j.1365-2125.2000.00175.x","article-title":"In vitro inhibition of the cytochrome P450 (CYP) system by the antiplatelet drug ticlopidine: potent effect on CYP2C19 and CYP2D6","volume":"49","author":"Ko","year":"2000","journal-title":"Br J Clin Pharmacol"},{"key":"10.1124\/dmd.106.014472_bib18","first-page":"853","article-title":"Evaluation of omeprazole and lansoprazole as inhibitors of cytochrome P450 isoforms","volume":"25","author":"Ko","year":"1997","journal-title":"Drug Metab Dispos"},{"key":"10.1124\/dmd.106.014472_bib19","doi-asserted-by":"crossref","first-page":"481","DOI":"10.1111\/j.1365-2125.1995.tb05793.x","article-title":"The effects of selective serotonin reuptake inhibitors and their metabolites on S-mephenytoin 4\u2032-hydroxylase activity in human liver microsomes","volume":"40","author":"Kobayashi","year":"1995","journal-title":"Br J Clin Pharmacol"},{"key":"10.1124\/dmd.106.014472_bib20","doi-asserted-by":"crossref","first-page":"821","DOI":"10.1124\/dmd.32.8.821","article-title":"Comparison of inhibitory effects of the proton pump-inhibiting drugs omeprazole, esomeprazole, lansoprazole, pantoprazole, and rabeprazole on human cytochrome P450 activities","volume":"32","author":"Li","year":"2004","journal-title":"Drug Metab Dispos"},{"key":"10.1124\/dmd.106.014472_bib21","doi-asserted-by":"crossref","first-page":"361","DOI":"10.2165\/00003088-199835050-00003","article-title":"Inhibition and induction of cytochrome P450 and the clinical implications","volume":"35","author":"Lin","year":"1998","journal-title":"Clin Pharmacokinet"},{"key":"10.1124\/dmd.106.014472_bib22","doi-asserted-by":"crossref","first-page":"103","DOI":"10.1124\/dmd.106.011601","article-title":"A real-time fluorescence assay for measuring N-dealkylation","volume":"35","author":"Mayer","year":"2007","journal-title":"Drug Metab Dispos"},{"key":"10.1124\/dmd.106.014472_bib23","doi-asserted-by":"crossref","first-page":"84","DOI":"10.1002\/j.1875-9114.1998.tb03830.x","article-title":"Update: clinically significant cytochrome P-450 drug interactions","volume":"18","author":"Michalets","year":"1998","journal-title":"Pharmacotherapy"},{"key":"10.1124\/dmd.106.014472_bib24","doi-asserted-by":"crossref","first-page":"365","DOI":"10.1096\/fasebj.1.5.3315805","article-title":"Fitting curves to data using nonlinear regression: a practical and nonmathematical review","volume":"1","author":"Motulsky","year":"1987","journal-title":"FASEB J"},{"key":"10.1124\/dmd.106.014472_bib25","doi-asserted-by":"crossref","first-page":"1509","DOI":"10.1124\/dmd.32.12.1509","article-title":"Use of a benzyloxy-substituted lactone cyclooxygenase-2 inhibitor as a selective fluorescent probe for CYP3A activity in primary cultured rat and human hepatocytes","volume":"32","author":"Nicoll-Griffith","year":"2004","journal-title":"Drug Metab Dispos"},{"key":"10.1124\/dmd.106.014472_bib26","doi-asserted-by":"crossref","first-page":"555","DOI":"10.1021\/tx980248q","article-title":"Design, synthesis, and characterization of 7-methoxy-4-(aminomethyl)-coumarin as a novel and selective cytochrome P450 2D6 substrate suitable for high-throughput screening","volume":"12","author":"Onderwater","year":"1999","journal-title":"Chem Res Toxicol"},{"key":"10.1124\/dmd.106.014472_bib27","doi-asserted-by":"crossref","first-page":"321","DOI":"10.2165\/00003088-198712050-00002","article-title":"Pharmacokinetic interactions of cimetidine 1987","volume":"12","author":"Somogyi","year":"1987","journal-title":"Clin Pharmacokinet"},{"key":"10.1124\/dmd.106.014472_bib28","doi-asserted-by":"crossref","first-page":"1440","DOI":"10.1016\/S0090-9556(24)13672-0","article-title":"Substrate-dependent modulation of CYP3A4 catalytic activity: analysis of 27 test compounds with four fluorometric substrates","volume":"28","author":"Stresser","year":"2000","journal-title":"Drug Metab Dispos"},{"key":"10.1124\/dmd.106.014472_bib29","doi-asserted-by":"crossref","first-page":"845","DOI":"10.1124\/dmd.30.7.845","article-title":"Cytochrome P450 fluorometric substrates: identification of isoform-selective probes for rat CYP2D2 and human CYP3A4","volume":"30","author":"Stresser","year":"2002","journal-title":"Drug Metab Dispos"},{"key":"10.1124\/dmd.106.014472_bib30","doi-asserted-by":"crossref","first-page":"235","DOI":"10.1124\/dmd.30.3.235","article-title":"(+)-N-3-benzyl-nirvanol and (-)-N-3-benzyl-phenobarbital: new potent and selective in vitro inhibitors of CYP2C19","volume":"30","author":"Suzuki","year":"2002","journal-title":"Drug Metab Dispos"},{"key":"10.1124\/dmd.106.014472_bib31","doi-asserted-by":"crossref","first-page":"231","DOI":"10.1081\/DMR-120033999","article-title":"Modeling kinetic data from in vitro drug metabolism enzyme experiments","volume":"36","author":"Tracy","year":"2004","journal-title":"Drug Metab Rev"},{"key":"10.1124\/dmd.106.014472_bib32","doi-asserted-by":"crossref","first-page":"1071","DOI":"10.1023\/A:1010994022294","article-title":"Optimizing drug development: strategies to assess drug metabolism\/transporter interaction potential\u2014toward a consensus","volume":"18","author":"Tucker","year":"2001","journal-title":"Pharm Res (NY)"},{"key":"10.1124\/dmd.106.014472_bib33","doi-asserted-by":"crossref","first-page":"1524","DOI":"10.1016\/S0090-9556(24)11801-6","article-title":"Influence of N-substitution of 7-methoxy-4-(aminomethyl)-coumarin on cytochrome P450 metabolism and selectivity","volume":"28","author":"Venhorst","year":"2000","journal-title":"Drug Metab Dispos"},{"key":"10.1124\/dmd.106.014472_bib34","doi-asserted-by":"crossref","first-page":"151","DOI":"10.1016\/S0928-0987(00)00150-0","article-title":"Evaluation of a novel high-throughput assay for cytochrome P450 2D6 using 7-methoxy-4-(aminomethyl)-coumarin","volume":"12","author":"Venhorst","year":"2000","journal-title":"Eur J Pharm Sci"},{"key":"10.1124\/dmd.106.014472_bib35","doi-asserted-by":"crossref","first-page":"647","DOI":"10.1124\/dmd.32.6.647","article-title":"Validated assays for human cytochrome P450 activities","volume":"32","author":"Walsky","year":"2004","journal-title":"Drug Metab Dispos"},{"key":"10.1124\/dmd.106.014472_bib36","doi-asserted-by":"crossref","first-page":"955","DOI":"10.1124\/dmd.31.7.955","article-title":"Cytochrome P450 inhibition using recombinant proteins and mass spectrometry\/multiple reaction monitoring technology in a cassette incubation","volume":"31","author":"Weaver","year":"2003","journal-title":"Drug Metab Dispos"},{"key":"10.1124\/dmd.106.014472_bib37","doi-asserted-by":"crossref","first-page":"239","DOI":"10.1016\/S0928-0987(02)00002-7","article-title":"Factors confounding the successful extrapolation of in vitro CYP3A inhibition information in the in vivo condition","volume":"15","author":"Wienkers","year":"2002","journal-title":"Eur J Pharm Sci"},{"key":"10.1124\/dmd.106.014472_bib38","series-title":"Foye\u2019s Principles of Medicinal Chemistry","first-page":"174","article-title":"Drug metabolism","author":"Williams","year":"2002"},{"key":"10.1124\/dmd.106.014472_bib39","doi-asserted-by":"crossref","first-page":"823","DOI":"10.1080\/0049825031000140887","article-title":"High-throughput screening to estimate single or multiple enzymes involved in drug metabolism: microtitre plate assay using a combination of recombinant CYP2D6 and human liver microsomes","volume":"33","author":"Yamamoto","year":"2003","journal-title":"Xenobiotica"},{"key":"10.1124\/dmd.106.014472_bib40","doi-asserted-by":"crossref","first-page":"403","DOI":"10.2174\/1568026013395001","article-title":"Metabolic profiling, and cytochrome P450 inhibition & induction in drug discovery","volume":"1","author":"Yan","year":"2001","journal-title":"Curr Topics Med Chem"},{"key":"10.1124\/dmd.106.014472_bib41","doi-asserted-by":"crossref","first-page":"565","DOI":"10.1124\/dmd.31.5.565","article-title":"Comparison of in vitro and in vivo inhibition potencies of fluvoxamine toward CYP2C19","volume":"31","author":"Yao","year":"2003","journal-title":"Drug Metab Dispos"},{"key":"10.1124\/dmd.106.014472_bib42","doi-asserted-by":"crossref","first-page":"266","DOI":"10.1067\/mcp.2001.114231","article-title":"Effect of meprazole on the pharmacokinetics of moclobemide according to the genetic polymorphism of CYP2C19","volume":"69","author":"Yu","year":"2001","journal-title":"Clin Pharmacol Ther"}],"container-title":["Drug Metabolism and Disposition"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0090955624013084?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0090955624013084?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/syndication.highwire.org\/content\/doi\/10.1124\/dmd.106.014472","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,2,18]],"date-time":"2025-02-18T16:25:39Z","timestamp":1739895939000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0090955624013084"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2007,6]]},"references-count":42,"journal-issue":{"issue":"6","published-print":{"date-parts":[[2007,6]]}},"alternative-id":["S0090955624013084"],"URL":"https:\/\/doi.org\/10.1124\/dmd.106.014472","relation":{},"ISSN":["0090-9556"],"issn-type":[{"value":"0090-9556","type":"print"}],"subject":[],"published":{"date-parts":[[2007,6]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Evaluation of 3-O-Methylfluorescein as a Selective Fluorometric Substrate for CYP2C19 in Human Liver Microsomes","name":"articletitle","label":"Article Title"},{"value":"Drug Metabolism and Disposition","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1124\/dmd.106.014472","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2007 The American Society for Pharmacology and Experimental Therapeutics","name":"copyright","label":"Copyright"}]}}